Astria Therapeutics, Inc. ATXS
At closeJan 23, 2026, 4:00 PM EST
After hours · Jan 23, 4:00 PM ET
52-week range unavailable
- YTD
- -3.90%
- 1 year
- +66.62%
- Market cap
- 538.38M
- Shares out
- 56.43M
- Forward P/E
- -5.39
- YTD return
- -3.90%
- 1-year return
- +66.62%
- Volume
- 3.06M
- Open
- 12.58
- Previous close
- 12.58
- Day's range
- 12.58 – 12.58
- Analysts
- Strong Buy
- Price target
- 26.43 (+110.1%)
Key statistics
- Enterprise value
- 309.44M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -56.60M
- Total cash
- 344.28M
- Total debt
- 5.64M
- Return on equity
- -38.03%
- Short % of float
- 5.79%
- 50-day average
- 10.63
- 200-day average
- 10.85
Analyst view
Consensus: strong buy
- Target (low)
- 16.00
- Target (mean)
- 26.43
- Target (high)
- 35.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.42 | -0.42 | 0.00 | 0.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.37 | -0.43 | -0.06 | -16.22% |
| May 9, 2024 | Mar 1, 2024 | -0.35 | -0.38 | -0.03 | -8.57% |
| Mar 4, 2024 | Dec 1, 2023 | -0.69 | -0.86 | -0.17 | -24.64% |
| Nov 13, 2023 | Sep 1, 2023 | -0.51 | -0.63 | -0.12 | -23.53% |
| Aug 7, 2023 | Jun 1, 2023 | -0.50 | -0.45 | +0.05 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | Oppenheimer | main | Outperform | Outperform |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wedbush | reit | Outperform | Outperform |
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- astriatx.com
News
Astria Stockholders Vote to Approve Acquisition by BioCryst 
Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS) 
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened 
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS 
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights 
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights 
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold 
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights 
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates 
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Your note
Sign in to keep a note on ATXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MORABITO CHRISTOPHER | Officer | Sale | Mar 31, 2024 | 0 |
| PERCEPTIVE ADVISORS LLC | Director | Purchase | Jan 31, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.86% | 7,822,275 | 74.62M | Sep 29, 2024 |
| Perceptive Advisors Llc | 11.49% | 6,485,420 | 61.87M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.05% | 5,105,213 | 48.70M | Sep 29, 2024 |
| Vestal Point Capital, LP | 7.09% | 4,000,000 | 38.16M | Sep 29, 2024 |
| Fairmount Funds Management LLC | 6.30% | 3,554,129 | 33.91M | Sep 29, 2024 |
| Blackrock Inc. | 6.20% | 3,499,478 | 33.39M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.77% | 1,560,542 | 14.89M | Sep 29, 2024 |
| Fidelity Small Cap Growth Fund | 2.40% | 1,354,456 | 12.92M | Aug 30, 2024 |
| iShares Russell 2000 ETF | 2.05% | 1,156,866 | 11.04M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.73% | 978,738 | 9.34M | Oct 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 1.46% | 824,805 | 7.87M | Aug 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.09% | 613,547 | 5.85M | Sep 29, 2024 |